A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen
about
GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancerGenomic profiling in luminal breast cancerYin Yang gene expression ratio signature for lung cancer prognosisGenomancy: predicting tumour response to cancer therapy based on the oracle of genetics.Pathways to tamoxifen resistance.Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer.A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancerA comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG studyPharmacogenetics and pharmacogenomics of anticancer agents.Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?Analysis of the Hox epigenetic code.Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancerPrediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patientsIn silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers.Re-evaluating early breast neoplasia.An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status.Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.HOX genes: Major actors in resistance to selective endocrine response modifiers.Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.Markers of endocrine sensitivityMUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.Gene expression profiling: changing face of breast cancer classification and management.Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.Genomic predictors of outcome and treatment response in breast cancer.Preinvasive breast cancer.Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.Integrating breast cancer genetics into clinical practice.Engrailed homeobox transcription factors as potential markers and targets in cancer.Novel molecular prognostic markers in breast cancer.Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.
P2860
Q21560759-C5DDBB25-3B76-4AC4-A8A9-2DC37DD580B4Q26862681-F9C18CD0-6A82-4841-8BAF-2A2788FFB9E2Q28385778-150C7E8E-05BD-41A9-A31D-E05D8C9506A7Q30440216-B378C47A-1406-49F0-BBD4-5E9039416967Q30441001-7B8945C9-51D9-4AA5-8D0C-E707D0A35432Q30854643-6146EC05-EC41-487E-A6CD-07B08143C9C1Q33684843-DE5C70ED-7BEF-4846-8DF4-CCEB890C0F68Q33834198-44519C1E-4525-456B-ABEC-8B47C5B65B89Q33974237-A586F85A-D126-4429-B58F-2168D6F9229FQ34029272-71F6E38C-9B53-491B-8FD7-2B6A0F0034EDQ34173474-C99C725D-A1F9-4053-A9C4-CBCE8F5C8741Q34268261-DA7AFCD5-52D3-4584-90A1-024A625872A0Q34311300-C897C3AD-C704-4FDC-B918-6138E6D37D19Q34559124-E7F04774-25D3-4FA3-AC47-934BA0C45F25Q35030489-0CF2BD3B-DD1D-44DA-A030-92B1673FDC0BQ35034575-471EC930-9F81-4FA3-8AFB-02A9A95C9043Q35622059-83B43787-489B-48DC-9666-38BA0AF16A90Q35926749-35A083C2-108B-430A-A30C-D9F272AF2FB2Q36047387-827A4AA4-5E72-417D-AA5D-09546AC58C70Q36101379-F9BFB424-5502-41F0-8CC9-A777FD719949Q36117673-CF469263-D3FD-48AA-9E7D-C1491657B669Q36629870-8AEC92CE-062B-4179-B5EA-70BD9F8971F9Q36643056-ABF88731-A5C2-4E20-AA62-98ED64197AEDQ36742417-9EFD3872-4C05-4859-9EA8-2B3D6019C296Q36816034-B340AC9C-BDBB-46AD-80A6-B6EFD6C653DAQ36880407-0D6199CA-1EE1-499D-8289-534C6AD522E8Q37000701-9062DFBE-39A7-41CD-9B40-563635166537Q37039792-2215D270-077D-4FD1-A77A-E506741D2825Q37130478-91AB91CC-0A4F-4694-A991-A32C17E2882FQ37169835-6718C3E5-6AD8-452D-B412-7442BC9BDD55Q37345983-6108B574-C892-44DD-96FD-878069A09343Q37356684-FD72EE76-D0DA-4DE9-8624-7E37B9FBA0F1Q37463330-C2562017-288D-4FE4-AE07-AEA77C1A0322Q37523889-F9476935-40FF-46DB-818C-CF6334932E7BQ37569919-20EF3FB5-526B-4A31-8088-14F1E1D85E0CQ37871407-E9DC985C-26AA-41EE-A526-109D8EEE0710Q37968654-FFAB5C86-7B61-4033-8443-9C11B3979BC7Q38080336-49EDD0E8-F01D-4BAF-9F6B-0AECA4F2919AQ38089820-886E9486-7D2A-4B8C-B8E0-3C8E650FEA61Q38165072-050D9988-8609-46FD-9136-923D609C1E70
P2860
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@ast
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@en
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@nl
type
label
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@ast
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@en
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@nl
prefLabel
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@ast
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@en
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@nl
P2093
P1476
A two-gene expression ratio of ...... n receiving adjuvant tamoxifen
@en
P2093
Andrea M Nibbe
Carol A Reynolds
Dan W Visscher
Dennis C Sgroi
Edith A Perez
James N Ingle
Mark Erlander
Matthew P Goetz
Vera J Suman
Wilma L Lingle
P304
P356
10.1158/1078-0432.CCR-05-1263
P407
P433
P577
2006-04-01T00:00:00Z